| scholarly article | Q13442814 |
| P2093 | author name string | Qing Wang | |
| Ismael J Hidalgo | |||
| Jibin Li | |||
| Glenn L Dobson | |||
| Joseph D Rager | |||
| Kathryn Weinstein | |||
| Paula S Kardos | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cell line | Q21014462 |
| blood–brain barrier | Q221694 | ||
| P304 | page(s) | 349-359 | |
| P577 | publication date | 2004-12-15 | |
| P1433 | published in | International Journal of Pharmaceutics | Q6051539 |
| P1476 | title | Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier. | |
| P478 | volume | 288 |
| Q38705793 | A CRISPR-Cas9 Generated MDCK Cell Line Expressing Human MDR1 Without Endogenous Canine MDR1 (cABCB1): An Improved Tool for Drug Efflux Studies. |
| Q64068149 | A Novel Three-Dimensional Glioma Blood-Brain Barrier Model for High-Throughput Testing of Tumoricidal Capability |
| Q34789397 | A new in situ brain perfusion flow correction method for lipophilic drugs based on the pH-dependent Crone-Renkin equation |
| Q57684720 | ADME |
| Q90113025 | APP Maturation and Intracellular Localization Are Controlled by a Specific Inhibitor of 37/67 kDa Laminin-1 Receptor in Neuronal Cells |
| Q36715672 | Alternating magnetic field-induced hyperthermia increases iron oxide nanoparticle cell association/uptake and flux in blood-brain barrier models |
| Q39440958 | Analysis of transcriptomic and proteomic profiles demonstrates improved Madin-Darby canine kidney cell function in a renal microfluidic biochip |
| Q37096694 | Analytical and biological methods for probing the blood-brain barrier |
| Q33530732 | Anti-malarial activity of a non-piperidine library of next-generation quinoline methanols |
| Q40192152 | Assessment of the first and second generation antihistamines brain penetration and role of P-glycoprotein |
| Q36316489 | Atenolol Renal Secretion Is Mediated by Human Organic Cation Transporter 2 and Multidrug and Toxin Extrusion Proteins |
| Q40117966 | Avermectin transepithelial transport in MDR1- and MRP-transfected canine kidney monolayers |
| Q88453672 | Blocking Alcoholic Steatosis in Mice with a Peripherally Restricted Purine Antagonist of the Type 1 Cannabinoid Receptor |
| Q64042313 | Brain Penetrable Histone Deacetylase 6 Inhibitor SW-100 Ameliorates Memory and Learning Impairments in a Mouse Model of Fragile X Syndrome |
| Q34243408 | Brainpeps: the blood-brain barrier peptide database |
| Q34707666 | Challenges for blood-brain barrier (BBB) screening |
| Q30651426 | Challenges of using in vitro data for modeling P-glycoprotein efflux in the blood-brain barrier |
| Q41920365 | Comparison of MDCK-MDR1 and Caco-2 cell based permeability assays for anti-malarial drug screening and drug investigations |
| Q36755346 | Design of 4-Oxo-1-aryl-1,4-dihydroquinoline-3-carboxamides as Selective Negative Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 2. |
| Q39177389 | Design, synthesis and evaluation of 3-(2-aminoheterocycle)-4-benzyloxyphenylbenzamide derivatives as BACE-1 inhibitors. |
| Q37284843 | Design, synthesis, and biological evaluation of (E)-N-aryl-2-arylethenesulfonamide analogues as potent and orally bioavailable microtubule-targeted anticancer agents |
| Q48116127 | Discovery of N-(5-Fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (VU0424238): A Novel Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Selected for Clinical Evaluation |
| Q48182438 | Discovery of Novel Proline-Based Neuropeptide FF Receptor Antagonists. |
| Q42728918 | Discovery of VU0431316: a negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety |
| Q36733346 | Discovery of a Selective and CNS Penetrant Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 3 with Antidepressant and Anxiolytic Activity in Rodents |
| Q47729702 | Discovery of imidazo[1,2-a]-, [1,2,4]triazolo[4,3-a]-, and [1,2,4]triazolo[1,5-a]pyridine-8-carboxamide negative allosteric modulators of metabotropic glutamate receptor subtype 5. |
| Q89855148 | Drug Development for Central Nervous System Diseases Using In Vitro Blood-brain Barrier Models and Drug Repositioning |
| Q33995372 | Drug delivery across the blood-brain barrier: why is it difficult? how to measure and improve it? |
| Q33946973 | Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery |
| Q47260839 | Effects of particle size and surface modification on cellular uptake and biodistribution of polymeric nanoparticles for drug delivery |
| Q39579486 | Effects of surface modification on delivery efficiency of biodegradable nanoparticles across the blood-brain barrier |
| Q48854460 | Elucidation of Transport Mechanism of Paeoniflorin and the Influence of Ligustilide, Senkyunolide I and Senkyunolide A on Paeoniflorin Transport through Mdck-Mdr1 Cells as Blood-Brain Barrier in Vitro Model. |
| Q47163222 | Engineering the human blood-brain barrier in vitro |
| Q37286215 | Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogen |
| Q21144517 | Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness |
| Q38726925 | Gb3-binding lectins as potential carriers for transcellular drug delivery |
| Q30540417 | Highly stabilized curcumin nanoparticles tested in an in vitro blood-brain barrier model and in Alzheimer's disease Tg2576 mice |
| Q28551318 | Human Brain Microvascular Endothelial Cells Derived from the BC1 iPS Cell Line Exhibit a Blood-Brain Barrier Phenotype |
| Q48564258 | Hydrophilic anti-migraine triptans are substrates for OATP1A2, a transporter expressed at human blood-brain barrier |
| Q42863806 | Identification of 2-oxo-N-(phenylmethyl)-4-imidazolidinecarboxamide antagonists of the P2X7 receptor |
| Q99548736 | Identification of Potential COX-2 Inhibitors for the Treatment of Inflammatory Diseases Using Molecular Modeling Approaches |
| Q43818035 | Identification of two immortalized cell lines, ECV304 and bEnd3, for in vitro permeability studies of blood-brain barrier |
| Q36394062 | Improving the prediction of the brain disposition for orally administered drugs using BDDCS. |
| Q38758994 | In vitro characterization of pralidoxime transport and acetylcholinesterase reactivation across MDCK cells and stem cell-derived human brain microvascular endothelial cells (BC1-hBMECs). |
| Q89057060 | In vitro models of molecular and nano-particle transport across the blood-brain barrier |
| Q38081102 | In vitro, in vivo and in silico models of drug distribution into the brain |
| Q36744766 | Influence of overexpression of efflux proteins on the function and gene expression of endogenous peptide transporters in MDR-transfected MDCKII cell lines |
| Q92011213 | Inhibition of Rac1-dependent forgetting alleviates memory deficits in animal models of Alzheimer's disease |
| Q41933038 | Integrated pharmacokinetic-driven approach to screen candidate anticancer drugs for brain tumor chemotherapy |
| Q38117056 | Methodologies to assess drug permeation through the blood-brain barrier for pharmaceutical research |
| Q31034258 | Methods to assess drug permeability across the blood-brain barrier |
| Q39424092 | Methotrexate-loaded chitosan- and glycol chitosan-based nanoparticles: a promising strategy for the administration of the anticancer drug to brain tumors. |
| Q37671826 | Mitigating permeability-mediated risks in drug discovery |
| Q37418045 | Modulation of multiple pathways involved in the maintenance of neuronal function during aging by fisetin |
| Q33792474 | New perspective for the treatment of Alzheimer diseases: liposomal rivastigmine formulations |
| Q34906375 | Novel method to label solid lipid nanoparticles with 64cu for positron emission tomography imaging. |
| Q38186650 | Overview of experimental models of the blood-brain barrier in CNS drug discovery |
| Q41998110 | Paclitaxel C-10 carbamates: potential candidates for the treatment of neurodegenerative tauopathies |
| Q58924064 | Periosteum, bone's “smart” bounding membrane, exhibits direction-dependent permeability |
| Q38754299 | Peripherally Selective Cannabinoid 1 Receptor (CB1R) Agonists for the Treatment of Neuropathic Pain |
| Q35057548 | Preclinical studies of the potent and selective nicotinic α4β2 receptor ligand VMY-2-95 |
| Q47739619 | Predicting apparent passive permeability of Caco-2 and MDCK cell-monolayers: A mechanistic model |
| Q28478693 | Predicting binding to p-glycoprotein by flexible receptor docking |
| Q42114873 | Predicting efflux ratios and blood-brain barrier penetration from chemical structure: combining passive permeability with active efflux by P-glycoprotein |
| Q41148725 | Predicting the extent of metabolism using in vitro permeability rate measurements and in silico permeability rate predictions |
| Q38996273 | Preparation, transportation mechanisms and brain-targeting evaluation in vivo of a chemical delivery system exploiting the blood-cerebrospinal fluid barrier |
| Q35715564 | Property-based design of a glucosylceramide synthase inhibitor that reduces glucosylceramide in the brain. |
| Q38583312 | Pyrazole antagonists of the CB1 receptor with reduced brain penetration |
| Q38570611 | Reliability of In Vitro and In Vivo Methods for Predicting the Effect of P-Glycoprotein on the Delivery of Antidepressants to the Brain |
| Q43214475 | Revisiting atenolol as a low passive permeability marker. |
| Q27490844 | SCY-635, a Novel Nonimmunosuppressive Analog of Cyclosporine That Exhibits Potent Inhibition of Hepatitis C Virus RNA Replication In Vitro |
| Q39387222 | Screening candidate anticancer drugs for brain tumor chemotherapy: pharmacokinetic-driven approach for a series of (E)-N-(substituted aryl)-3-(substituted phenyl)propenamide analogues |
| Q53341299 | Steady-state plasma concentration of donepezil enantiomers and its stereoselective metabolism and transport in vitro. |
| Q38090672 | Strategies to assess blood-brain barrier penetration |
| Q36276693 | Structure-activity relationships and pharmacophore model of a noncompetitive pyrazoline containing class of GluN2C/GluN2D selective antagonists |
| Q34083438 | Studies toward the Development of Antiproliferative Neoclerodanes from Salvinorin A. |
| Q34818171 | TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs |
| Q38799834 | The Blood-Brain Barrier Permeability of Lignans and Malabaricones from the Seeds of Myristica fragrans in the MDCK-pHaMDR Cell Monolayer Model. |
| Q47975514 | The Blood-Brain Barrier Permeability of Six Indole Alkaloids from Uncariae Ramulus Cum Uncis in the MDCK-pHaMDR Cell Monolayer Model |
| Q34587678 | The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer's disease and related tauopathies |
| Q47940999 | The influence and mechanism of ligustilide, senkyunolide I, and senkyunolide A on echinacoside transport through MDCK-MDR1 cells as blood-brain barrier in vitro model |
| Q38560853 | Tools for studying drug transport and metabolism in the brain |
| Q31119557 | Towards Better BBB Passage Prediction Using an Extensive and Curated Data Set. |
| Q38382015 | Towards rational design of cannabinoid receptor 1 (CB1) antagonists for peripheral selectivity |
| Q39055000 | Toxicity Studies on Novel N-Substituted Bicyclo-Heptan-2-Amines at NMDA Receptors |
| Q47400136 | Transport of Twelve Coumarins from Angelicae Pubescentis Radix across a MDCK-pHaMDR Cell Monolayer-An in Vitro Model for Blood-Brain Barrier Permeability. |
| Q36691249 | Unravelling the complex drug-drug interactions of the cardiovascular drugs, verapamil and digoxin, with P-glycoprotein |
| Q36344515 | Urea-based inhibitors of Trypanosoma brucei methionyl-tRNA synthetase: selectivity and in vivo characterization. |
| Q36319277 | Use of biopartitioning micellar chromatography and RP-HPLC for the determination of blood-brain barrier penetration of α-adrenergic/imidazoline receptor ligands, and QSPR analysis |
| Q84498183 | Validation of quinidine as a probe substrate for the in vitro P-gp inhibition assay in Caco-2 cell monolayer |
| Q45893532 | Variability of permeability estimation from different protocols of subculture and transport experiments in cell monolayers. |
Search more.